Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 13, 2018 - Issue
Submit an article Journal homepage
136
Views
25
CrossRef citations to date
0
Altmetric
Original Research

Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study

Alejandro Casas1 Fundación Neumológica Colombiana, Universidad del Rosario, Bogotá, ColombiaCorrespondence[email protected]
,
Maria Montes de Oca2 Universidad Central de Venezuela, Caracas, Venezuela
,
Ana MB Menezes3 Federal University of Pelotas, Pelotas, Brazil
,
Fernando C Wehrmeister3 Federal University of Pelotas, Pelotas, Brazil
,
Maria Victorina Lopez Varela4 Universidad de la República, Montevideo, Uruguay
,
Laura Mendoza5 Hospital Clínico Universidad de Chile, Santiago de Chile, Chile
,
Larissa Ramírez6 AstraZeneca, San José, Costa Rica
&
Marc Miravitlles7 Department of Pneumology, Hospital Universitari Vall d’Hebron, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain
 show all
Pages 1545-1556 | Published online: 11 May 2018

Figures & data

Table 1 Patients’ characteristics, overall and by country

Table 2 Clinical profile of patients according to type of medication used

Figure 1 Type and frequency of medication used, overall and by country.

Note: LABA, LAMA, LABA/LAMA, ICS, ICS/LABA, ICS/LAMA/LABA, and ICS/LAMA could be used alone or in combination with SABA or SAMA.
Abbreviations: LABA, long-acting β-agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroid; SABA, short-acting β-agonist; SAMA, short-acting muscarinic antagonist.
Figure 1 Type and frequency of medication used, overall and by country.

Figure 2 Type of medication used according to the GOLD 2013 stage classification in the overall population.

Note: LABA, LAMA, LABA/LAMA, ICS, ICS/LABA, ICS/LAMA/LABA, and ICS/LAMA could be used alone or in combination with SABA or SAMA.
Abbreviations: GOLD, Global Initiative for Chronic Obstructive Lung Disease; LABA, long-acting β-agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroid; SABA, short-acting β-agonist; SAMA, short-acting muscarinic antagonist.
Figure 2 Type of medication used according to the GOLD 2013 stage classification in the overall population.

Figure 3 Adherence to treatment (TAI questionnaire) according to the type of medication used in the overall population.

Note: LABA, LAMA, LABA/LAMA, ICS, ICS/LABA, ICS/LAMA/LABA, and ICS/LAMA could be used alone or in combination with SABA or SAMA.
Abbreviations: TAI, Test of Adherence to Inhalers; LABA, long-acting β-agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroid; SABA, short-acting β-agonist; SAMA, short-acting muscarinic antagonist.
Figure 3 Adherence to treatment (TAI questionnaire) according to the type of medication used in the overall population.

Figure S1 Pattern of use of respiratory medication, either as-needed or as regular maintenance therapy.

Abbreviations: SABA, short-acting β-agonist; SAMA, short-acting muscarinic antagonist; LABA, long-acting β-agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroid.

Figure S1 Pattern of use of respiratory medication, either as-needed or as regular maintenance therapy.Abbreviations: SABA, short-acting β-agonist; SAMA, short-acting muscarinic antagonist; LABA, long-acting β-agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroid.

Figure S2 Type of medication used according to prior medical diagnosis of asthma.

Abbreviations: SABA, short-acting β-agonist; SAMA, short-acting muscarinic antagonist; LABA, long-acting β-agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroid.

Figure S2 Type of medication used according to prior medical diagnosis of asthma.Abbreviations: SABA, short-acting β-agonist; SAMA, short-acting muscarinic antagonist; LABA, long-acting β-agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroid.

Figure S3 History of exacerbations (ambulatory or requiring hospitalization) in the past year.

Abbreviations: SABA, short-acting β-agonist; SAMA, short-acting muscarinic antagonist; LABA, long-acting β-agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroid.

Figure S3 History of exacerbations (ambulatory or requiring hospitalization) in the past year.Abbreviations: SABA, short-acting β-agonist; SAMA, short-acting muscarinic antagonist; LABA, long-acting β-agonist; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroid.

Table S1 Approval committees in the various countries involved in the LASSYC study

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.